Bayer Animal Health and VLPbio sign global collaboration agreement
Bayer Animal Health to strengthen its technology portfolio for biological
Bayer Animal Health GmbH and VLPbio - The Vaccines Company S.L. have signed a global collaboration agreement to discover and develop a new generation of immunotherapeutic solutions that address the high demand for innovative treatment options in the field of veterinary medicine.
Bayer Animal Health and VLPbio have agreed to jointly discover and develop immunotherapeutics for animals based on VLPbio´s technology, which is designed to induce specific immune responses against target pathologies. The two companies will share knowledge about animal diseases and develop strategic approaches towards customer-focused treatment alternatives.
The collaboration aims to create tools to shape the future of animal health and to develop new products for prevention and treatment of animal diseases, thereby improving animal well-being.
Dr. Douglas Hutchens, Bayer Animal Health’s Head of Drug Discovery, External Innovation & Chief Veterinary Officer, said: “This partnership will help us to intensify our focus on immunotherapeutics. We are proud to collaborate with one of the most innovative start-up companies in the industry and strongly believe that this partnership will enhance our innovation capabilities.”
VLPbio CEO Pablo Gutiérrez commented: “Our commitment to this collaboration is based on three competitive advantages of our company: the innovative potential of our technology, the experience and capacity of our team as well as a solid strategic plan.
This position is being recognized in the industry: VLPbio was one of 12 innovation showcase finalists to pitch for investment in their products and technologies in the field of Health at the Animal Health Investment Forum Europe 2019.”